Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.75 EUR | -1.60% | -0.15% | -16.09% |
Feb. 02 | Boiron: nearly 600,000 shares tendered to the OPAS | CF |
Jan. 11 | Boiron: OPAS open from January 11 to 31 | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The opinion of analysts covering the stock has improved over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.09% | 626M | B | ||
-15.13% | 4.51B | C+ | ||
-9.75% | 3.15B | B- | ||
+2.14% | 3.1B | C | ||
-6.82% | 2.42B | - | D+ | |
+47.87% | 1.97B | - | ||
+0.09% | 1.65B | - | - | |
-7.89% | 1.68B | - | - | |
-12.97% | 1.53B | C- | ||
+33.40% | 1.38B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BOI Stock
- Ratings BOIRON